MediGene presents preclinical AAVLP data at World Vaccine Congress
By BFN News | 08:31 AM | Tuesday 10 April, 2012
Biotech company MediGene announces that preclinical data from its AAVLP vaccine technology, will be presented tomorrow at the World Vaccine Congress 2012 in Washington DC, US.
The data show that vaccination of mice with an AAVLP vaccine carrying HPV L2 epitopes at two surface sites induces cross-neutralizing antibodies active against several HPV types, and provides stable protection against vaginal HPV challenge over three months when using a clinically relevant adjuvant.
Additional preclinical studies will be conducted with Medigene's AAVLP vaccine technology.
Story provided by StockMarketWire.com